sector medic suppli devic
messag ew broke littl new ground analyst meet someth
expect go given recent complet ssa clinic pathway culmin
low risk approv august still nascent state compani next
stabl potenti growth driver asymptomat moder mitral tricupsid
manag outlook also yield surpris bracket consensu top
bottom line reiter tavr market growth moder messag
call day light major announc import
increment takeaway view walk
conserv guidanc
prevail sentiment among investor weve spoken past week
manag call tavr market growth moder next year simpli
effort keep street expect check ew share trade ntm
ep believ stock bake assumpt compani initi tavr
guidanc cc turn meaning conserv much origin
guidanc expect vs actual howev see
low end rang unlik given momentum market today easi
comp first half year mid-teen growth strike us unreason
model assum edward ww tavr busi grow cc next year
volum gain market overal market growth visibl
market month admittedli limit today impact
low risk label expans still start felt potenti revis ncd
lead influx new tavr center tailwind like partial
off-set reduc contribut higher risk patient group increas competit
modest price pressur hospit qualifi volum discount initi
take outlook could turn less conserv guidanc
low risk book edward continu invest next wave potenti
growth driver compani remark clinic trial underway across
tmtt busi includ pivot studi yet activ tmtt
segment still like coupl year away signific contributor edward top
line possibl fda approv pascal treat degen mitral regurgit
patient set first major regulatori mileston manag expect tmtt
sale come near doubl level consensu
come thursday meet
meanwhil edward continu explor opportun tavr outsid
recoveri trial see takeaway demonstr savr could
markedli improv prognosi asymptomat patient sever compar
medic manag bode well earli tavr studi edward expect
complet enrol thursday meet compani focus potenti
expand treatment patient moder dr geoff strang australia
share intrigu data suggest popul fare almost poorli
classifi sever diseas crf-sponsor tavr unload trial
alreadi underway look group studi like small chang
clinic practic result think like edward need
moder trial point futur bring patient label
plenti worthwhil pipelin program invest like year
limit oper leverag guidanc call gross margin sg expens
spend hold roughli steadi level next year combin modest upward
page analyst certif import disclosur
pressur tax rate share count suggest edward ep growth like
hew close top line trajectori past year
long-term signific leverag beyond may also less like
bull assum edward increas spend percentag sale
past three year increas dollar term cfo scott ullem
hesit character current run rate sale peak level given
larg number shot goal compani continu cultiv pipelin meanwhil
edward high touch sale clinic support model kept sg rang
past three year guidanc call spend stay level
well thursday meet mr ullem laid set long-term guidanc paramet
includ expect minor oper margin expans time would seem
reflect realiti busi model believ spend
justifi result kind top line growth next year edward
enjoy past decad howev also think outlook call question
bull thesi ew share deserv signific premium large-cap med-tech
peer compani materi under-earn today manag effect
signal investor either continu strong top line growth signific margin
expans
adjust estim model call edward post ep
yoy total revenu organ compar prior forecast
respect long-term see edward
grower top bottom line respect outlook
reflect ew share current level view maintain neutral rate
page analyst certif import disclosur
edward one great med-tech success stori past decad
transform way valvular heart diseas treat process estim
world-wide tavr sale came cc edward busi
gener revenu cc work suggest tavr market
track reach sale next four year edward pois primari
beneficiari growth even competit increas howev street
expect acceler tavr market growth post low-risk label expans
alreadi high stock trade signific premium peer ntm ep vs
dont see risk/reward attract current level
edward share trade ntm ep estim ntm ebitda well
large-cap med-tech averag respect believ
edward best-in-class top-lin growth profil warrant premium valuat believ
premium valuat fulli reflect base case scenario tavr adopt
compani growth potenti next year better upsid
opportun elsewher group view remain neutral rate
upsid risk rate fair valu estim includ tavr market growth
exce street expect edward defend leadership posit world-wide
tavr share better forecast tmtt pipelin provid compani
meaning new growth driver sooner anticip
downsid risk rate fair valu estim includ tavr market growth
fall short street expect greater-than-expect share gain new tavr
competitor come market clinic and/or regulatori setback pipelin
program caus investor question sustain edward premium growth
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
